![AgTech Accelerator Makes First Animal Health Industry Investment in Skyline Vet Pharma with $5 Million Series A Financing | Business Wire AgTech Accelerator Makes First Animal Health Industry Investment in Skyline Vet Pharma with $5 Million Series A Financing | Business Wire](https://mms.businesswire.com/media/20170413005420/en/523360/21/AgTech_Logo.jpg)
AgTech Accelerator Makes First Animal Health Industry Investment in Skyline Vet Pharma with $5 Million Series A Financing | Business Wire
![AgTech Accelerator: AgTech Accelerator makes first animal health industry investment in Skyline Vet Pharma with $5 million financing - Research Triangle Regional Partnership AgTech Accelerator: AgTech Accelerator makes first animal health industry investment in Skyline Vet Pharma with $5 million financing - Research Triangle Regional Partnership](https://www.researchtriangle.org/wp-content/uploads/2018/09/skyline-vet.jpg)
AgTech Accelerator: AgTech Accelerator makes first animal health industry investment in Skyline Vet Pharma with $5 million financing - Research Triangle Regional Partnership
![AgTech Accelerator: AgTech Accelerator makes first animal health industry investment in Skyline Vet Pharma with $5 million financing - Research Triangle Regional Partnership AgTech Accelerator: AgTech Accelerator makes first animal health industry investment in Skyline Vet Pharma with $5 million financing - Research Triangle Regional Partnership](https://www.researchtriangle.org/wp-content/uploads/2018/09/raleigh.jpg)
AgTech Accelerator: AgTech Accelerator makes first animal health industry investment in Skyline Vet Pharma with $5 million financing - Research Triangle Regional Partnership
Lumosa Therapeutics Licenses Long Acting Injectable Analgesic to Skyline Vet Pharma, Inc. for Use in Companion Animals -January 16, 2018 at 05:22 am EST | MarketScreener
RTP-based AgTech Accelerator invests in Skyline Vet Pharma, an animal health company. | Durham Herald Sun
![JPM need-to-know, Part 2: Launch woes, crossed fingers, a 'bulletproof' FDA review and more | Fierce Pharma JPM need-to-know, Part 2: Launch woes, crossed fingers, a 'bulletproof' FDA review and more | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1546969046/15962514841_bae50917f0_k.jpg/15962514841_bae50917f0_k.jpg?VersionId=3ZSACH9F3pfJv3bcJlxEN1h65135bAeJ)